alexa Nanolipoblockers: Biomaterial Therapeutics Aimed At The Ground Zero Of Atherosclerosis And Heart Disease
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd Annual Conference and Expo on BIOMATERIALS
March 27-28, 2017 Madrid, Spain

Prabhas V Moghe
Rutgers University, USA
Posters & Accepted Abstracts: J Biotechnol Biomater
DOI: 10.4172/2155-952X.C1.074
Abstract
Statement of the Problem: The uncontrolled accumulation of oxidized low-density lipoproteins (LDL) within the walls of blood vessels, called atherosclerosis, lies at the core of cardiovascular diseases and causes a staggering toll on adult mortality and rising health care costs. Methodology & Innovation: Biomaterials as anti-atherosclerotic therapeutics for inhibiting cholesterol accumulation and the related inflammation. A generation of unimers whose surface features such as surface anionic density; amphiphilicity; and nanoscale architecture can be systematically varied was designed. Competitive binding to scavenger receptors was used as a key mechanism of action. Serum-stable nanoparticles were fabricated from the unimers using flash nanoprecipitation and the NLB nanoparticles were administered in vivo to treat the progression of atherosclerosis. Findings & Conclusions: We report that assemblies of such nanolipoblockers (NLBs) can systematically block the scavenger receptor molecules that traffic highly oxidized LDL into macrophages and inhibit the resulting atherogenic phenotype. In parallel, a multimodal strategy of depleting cellular cholesterol was examined by using the NLBs as drug delivery carriers in vivo. The NLBs lowered intimal levels of accumulated cholesterol and inhibited macrophage retention relative to non-treated controls. A number of more recent project directions, including studies of molecular mechanisms of action, design of more stable nanoparticle formulations of the NLBs, and emergent pathways for translational medicine will also be highlighted in this talk.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords